KilgourMD, the dermatologist-founded scalp health and hair growth brand created by Stanford-trained, board-certified dermatologist Dr. James Kilgour, today unveiled its most significant evolution to date.
The relaunch introduces a new visual identity and packaging, along with reformulated versions of the brand’s bestselling Prevention and Treatment Scalp Serums, featuring the company’s first two patent-pending active ingredients developed through biotechnology, GlycoRoot and AndroLock.
The rebrand follows a period of rapid growth. Launched in 2024, KilgourMD has reached more than $100 million in annualized revenue run rate, has served more than 250,000 customers and sells a bottle of product every 20 seconds. In March 2026, following a profitable 2025, the company closed a Series A led by Prelude Growth Partners to expand its proprietary ingredient pipeline and clinical research. This rebrand marks the first major milestone since that investment.
“When we launched KilgourMD, we had two serums and one conviction – hair loss deserves the same scientific rigor as any other medical concern,” said Dr. James Kilgour, founder and CEO of KilgourMD. “Today, our customers trust us with something deeply personal, and that raises the bar for everything we do. This next chapter introduces our first proprietary actives, packaging designed around how our customers use our products every day, and an identity that reflects who we are: a company built on clinical evidence and empathy.”
The reformulated KilgourMD System brings together two serums, a shampoo and a conditioner, designed as one routine:
- The Prevention Scalp Serum now features GlycoRoot, a proprietary, patent-pending active that uses glycogen nanoparticles to deliver a validated basil root extract deep into the hair follicle. In vitro testing has demonstrated that GlycoRoot restores normal trophic growth signaling in aging hair follicle cells, including a more than 215% increase in IGF-1 gene expression in testosterone-stressed cells, and a 172% relative increase in ex vivo hair follicle growth.
- The Treatment Scalp Serum now features AndroLock, a patent-pending and independently tested delivery technology that pairs saw palmetto with a bespoke proprietary delivery peptide to carry actives into the depths of the scalp where the follicle sits. The delivery peptide was shown in human skin microscopy studies to enhance saw palmetto delivery by 47%, and, in addition to suppressing DHT, gene expression studies on human scalp explants have shown that AndroLock can broadly enhance pro-growth pathways while delaying the resting phase of hair follicle growth.
- The Cleansing Shampoo is formulated to rebuild the scalp’s protective barrier, rebalance its microbiome and provide antioxidant defense, helping to calm irritation and reduce the appearance of flakes.
- The Fortifying Conditioner strengthens and protects the hair fiber, including fragile new hairs, without weighing hair down, and can also be used as a lightweight, bond-building leave-in.
The new formulas build on the system’s clinical foundation. In an independent, four-month clinical study of 43 menopausal-aged women with active hair shedding, published in the Journal of Drugs in Dermatology in June 2026, the KilgourMD System reduced shedding by 60.3% at four months, and 53% of participants showed clinically significant growth as assessed by two independent dermatologists.
KilgourMD’s new brand identity and packaging were developed under the direction of Chief Brand Officer, Dr. Soubhi Alhayek. The packaging was redesigned around customer feedback, with a precision dropper that dispenses a consistent dose with each use, paired with serums formulated to deliver key actives to the follicle.
“As we began this evolution, I wanted every detail to be fluent in the science and attuned to how personal hair loss is and the vulnerability it can create. The result is a brand that is as emotionally compelling as its science is rigorous,” said Dr. Kilgour.
The rebrand sets the stage for KilgourMD’s 2027 pipeline, including new categories and additional peer-reviewed clinical publications, two of which are currently in press.
Source: PR Newswire
